ACM
Altium Capital Management Portfolio holdings
AUM
$34.4M
This Quarter Return
-4.2%
1 Year Return
-2.5%
3 Year Return
+357.21%
5 Year Return
–
10 Year Return
–
AUM
$287M
AUM Growth
+$287M
(-19%)
Cap. Flow
-$53.8M
Cap. Flow
% of AUM
-18.75%
Top 10 Holdings %
Top 10 Hldgs %
27.44%
Holding
165
New
32
Increased
12
Reduced
17
Closed
46
Top Buys
| 1 |
PEPLU
PepperLime Health Acquisition Corporation Unit
PEPLU
|
$7.23M |
| 2 |
DexCom
DXCM
|
$6.4M |
| 3 |
Tandem Diabetes Care
TNDM
|
$5.82M |
| 4 |
Envista
NVST
|
$5.12M |
| 5 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$4.77M |
Top Sells
| 1 |
Lantheus
LNTH
|
$12.8M |
| 2 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
$8.8M |
| 3 |
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
|
$7.2M |
| 4 |
Immatics
IMTX
|
$6.32M |
| 5 |
NSTG
NanoString Technologies, Inc.
NSTG
|
$6.19M |
Sector Composition
| 1 | Healthcare | 81.73% |
| 2 | Financials | 7.62% |
| 3 | Industrials | 1.25% |
| 4 | Technology | 0.86% |
| 5 | Communication Services | 0.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Esperion Therapeutics
ESPR
$448M
| $11.6M | 3.88% | 2,496,524 -19,261 | -0.8% | -$89.4K |
|
|
BLU
2
DELISTED
BELLUS Health Inc.
BLU
| $9.98M | 3.34% | 1,450,006 | – | – |
|
3
Protagonist Therapeutics
PTGX
$3.67B
| $9.14M | 3.06% | 386,000 +40,000 | +12% | +$947K |
|
|
KDNY
4
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $8.92M | 2.98% | 545,000 | – | – |
|
|
PEPLU
5
DELISTED
PepperLime Health Acquisition Corporation Unit
PEPLU
| $7.23M | 2.42% | +735,000 | New | +$7.23M |
|
6
Keros Therapeutics
KROS
$618M
| $6.85M | 2.29% | 126,000 +10,000 | +9% | +$544K |
|
|
7
DexCom
DXCM
$29.5B
| $6.4M | 2.14% | +12,500 | New | +$6.4M |
|
8
Insmed
INSM
$28.8B
| $6.3M | 2.11% | 268,000 +64,646 | +32% | +$1.52M |
|
9
QuidelOrtho
QDEL
$1.95B
| $6.3M | 2.11% | 56,000 +19,000 | +51% | +$2.14M |
|
10
ADMA Biologics
ADMA
$4.12B
| $6.04M | 2.02% | 3,300,000 | – | – |
|
11
Globus Medical
GMED
$8.27B
| $5.83M | 1.95% | 79,000 +20,000 | +34% | +$1.48M |
|
|
12
Tandem Diabetes Care
TNDM
$845M
| $5.82M | 1.95% | +50,000 | New | +$5.82M |
|
|
NVRO
13
DELISTED
NEVRO CORP.
NVRO
| $5.57M | 1.86% | 77,000 +35,000 | +83% | +$2.53M |
|
14
Relmada Therapeutics
RLMD
$37.2M
| $5.56M | 1.86% | 206,000 | – | – |
|
|
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
| $5.44M | 1.82% | 1,750,000 | – | – |
|
16
Glaukos
GKOS
$5.5B
| $5.44M | 1.82% | 94,000 +13,000 | +16% | +$752K |
|
|
BCYC
17
Bicycle Therapeutics
BCYC
$511M
| $5.27M | 1.76% | 120,000 -52,000 | -30% | -$2.28M |
|
|
18
Envista
NVST
$3.52B
| $5.12M | 1.71% | +105,000 | New | +$5.12M |
|
|
MBTC
19
DELISTED
Nocturne Acquisition Corporation Ordinary Shares
MBTC
| $5.04M | 1.69% | 500,000 | – | – |
|
|
SWAV
20
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $4.77M | 1.6% | +23,000 | New | +$4.77M |
|
21
Karyopharm Therapeutics
KPTI
$61.7M
| $4.75M | 1.59% | +645,000 | New | +$4.75M |
|
22
Qiagen
QGEN
$10.1B
| $4.56M | 1.53% | 93,000 | – | – |
|
23
Avidity Biosciences
RNA
$5.99B
| $4.49M | 1.5% | 243,000 +18,000 | +8% | +$332K |
|
24
Crinetics Pharmaceuticals
CRNX
$2.92B
| $4.48M | 1.5% | 204,000 -127,000 | -38% | -$2.79M |
|
|
IMGN
25
DELISTED
Immunogen Inc
IMGN
| $4.38M | 1.47% | +920,000 | New | +$4.38M |
|